Tau-targeting antibody therapies: too late, wrong epitope or wrong target?
Tau-targeting antibody therapies: too late, wrong epitope or wrong target? | Nature
Medicine Skip to main content Thank you for visiting nature.com. You are using a browser
version with limited support for CSS. To obtain the best experience, we recommend you use
a more up to date browser (or turn off compatibility mode in Internet Explorer). In the
meantime, to ensure continued support, we are displaying the site without styles and
JavaScript. Advertisement Nature Medicine View all journals Search My Account Explore …
Medicine Skip to main content Thank you for visiting nature.com. You are using a browser
version with limited support for CSS. To obtain the best experience, we recommend you use
a more up to date browser (or turn off compatibility mode in Internet Explorer). In the
meantime, to ensure continued support, we are displaying the site without styles and
JavaScript. Advertisement Nature Medicine View all journals Search My Account Explore …
Two phase 2 studies of N-terminal tau–targeting antibody therapy fail to show clinical efficacy in progressive supranuclear palsy, despite evidence of target engagement.
nature.com